Table 2.
Demographics and clinical data of participants.
Mean ± SD | N | |
---|---|---|
Age at CHR-P Onset | 17.60 ± 3.63 | 92 |
Female, No. (%) | 35 (38.04) | 92 |
APS, No. (%) | 88 (95.65) | 92 |
BIPS, No. (%) | 9 (9.78) | 92 |
GRD, No. (%) | 15 (16.30) | 92 |
SPD diagnosis, No. (%) | 10 (10.87) | 92 |
SOPS Positive Score | 13.62 ± 3.65 | 91 |
SOPS Negative Score | 12.44 ± 6.37 | 91 |
SOPS Disorganization Score | 6.38 ± 3.77 | 91 |
SOPS General Score | 9.75 ± 4.27 | 91 |
Calculated Baseline Risk of Conversion | 26.20% ± 12.65 | 92 |
Decline in GAF in the Past Year | 13.98 ± 12.56 | 92 |
Decline in GFR in the Past Year | 1.54 ± 1.79 | 92 |
Decline in GFS in the Past Year | 0.99 ± 1.15 | 92 |
SOPS = Scale Of Psychosis-risk Symptoms; GFR Change = change in Global Role Function score in the year prior to baseline assessment; GFS Change = change in Global Social Function score in the year prior to baseline; GAF Change = change in Global Assessment of Functioning score in the year prior to baseline assessment; Baseline BIPS = presence of Brief Intermittent Psychosis Syndrome at baseline assessment; Baseline APS = presence of Attenuated Psychotic Symptom Syndrome at baseline assessment; Baseline GRD = presence of Genetic Risk and Deterioration Syndrome at baseline assessment; Baseline SPD = presence of Schizotypal Personality Disorder at baseline assessment; Calculated Risk = subject-wise calculated risk using the NAPLS Risk Calculator; Average Tanner Stage = self-reported average of pubic and penile/breast development at baseline assessment.